1. Signaling Pathways
  2. Anti-infection
  3. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-162474
    BZG2
    Inhibitor
    BZG2 is an allosteric inhibitor for the SARS-CoV-2 main protease (Mpro), with an IC50 of 77 µM.
    BZG2
  • HY-N13245
    Milk Thistle Extract
    Inhibitor
    Milk Thistle Extract is the extract of Milk Thistle, with content of 80% Silymarin.
    Milk Thistle Extract
  • HY-155980
    SARS-CoV-2 3CLpro-IN-17
    Inhibitor
    SARS-CoV-2 3CLpro-IN-17 (Compound 3h) is a selective SARS-CoV-2 3CLpro inhibitor (IC50s: 0.322 μM).
    SARS-CoV-2 3CLpro-IN-17
  • HY-170357
    SARS-CoV-2 3CLpro-IN-28
    Inhibitor
    SARS-CoV-2 3CLpro-IN-28 (Compound 19) is an inhibitor for SARS-CoV-2 3CLpro with an IC50 of 0.018 μM.
    SARS-CoV-2 3CLpro-IN-28
  • HY-149317
    ZINC475239213
    Inhibitor
    ZINC475239213 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 20 μM).
    ZINC475239213
  • HY-168441
    NCGC00537446
    Inhibitor
    NCGC00537446 is a dual Nsp14 MTase/ExoN inhibitor. NCGC00537446 can be used for the research of SARS-CoV-2 replication and infection.
    NCGC00537446
  • HY-150786
    PLP_Snyder530
    Inhibitor
    PLP_Snyder530 is a potent papain-like protease (PLpro) inhibitor with an IC50 value of 6.4 μM. PLP_Snyder530 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. PLP_Snyder530 can be used for SARS-CoV-2 research.
    PLP_Snyder530
  • HY-179334
    DMA-155
    Inhibitor
    DMA-155 is an antiviral agent with binding activity against SARS-CoV-2 5'-terminal stem-loop RNAs, with affinities of 51.1 μM (SL1), 61.1 μM (SL4), 54.5 μM (SL5a), 66.9 μM (SL5b) and 48.6 μM (SL6), respectively. DMA-155 inhibits SARS-CoV-2 viral replication and reduces SARS-CoV-2 viral RNA levels. DMA-155 is applicable to the research of COVID-19.
    DMA-155
  • HY-149314
    SARS-CoV-2-IN-47
    Inhibitor
    SARS-CoV-2-IN-47 (Compound 13) is a SARS-CoV-2 inhibitor (IC50: 0.77 μM against Omicron BA.1, 0.93 μM against Delta strain). SARS-CoV-2-IN-47 can be used for antiviral research.
    SARS-CoV-2-IN-47
  • HY-W816575
    MDI-403
    Inhibitor
    MDI-403 is a retinoic acid receptor (RAR) agonist with an EC50 value of less than 1 μM. MDI-403 exhibits significant antiviral activity against SARS-CoV-2, and can dose-dependently inhibit the expression of viral nucleoprotein (NP) and reduce the proportion of infected cells. MDI-403 mainly acts during the virus invasion stage. MDI-403 can be used in research on anti-SARS-CoV-2.
    MDI-403
  • HY-155679
    SARS-CoV-2 nsp14-IN-4
    Inhibitor
    SARS-CoV-2 nsp14-IN-4 (Compound 12q) is an inhibitor of SARS-CoV-2 nsp14 methyltransferase (IC50=19 nM). SARS-CoV-2 nsp14-IN-4 is non-cytotoxic and cell-permeable. SARS-CoV-2 nsp14-IN-4 is used in COVID-19 research.
    SARS-CoV-2 nsp14-IN-4
  • HY-170767
    SARS-CoV-2-IN-109
    Inhibitor
    SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting SARS-CoV with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC50=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC50=17.0 μM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM.
    SARS-CoV-2-IN-109
  • HY-149373
    Garcinone B
    Inhibitor
    Garcinone B, a xanthone derivative, is a nature product that could be isolated from the pericarp of Mangosteen. Garcinone B is a potent ACE2 and Mpro inhibitor. Garcinone B can be used in research of COVID-19.
    Garcinone B
  • HY-18219R
    Walrycin B (Standard)
    Inhibitor
    Walrycin B (Standard) is the analytical standard of Walrycin B. This product is intended for research and analytical applications. Walrycin B, an analogue of toxoflavin, is a potent SARS-CoV-2 3CLpro inhibitor with an IC50 of 0.26 μM. Walrycin B is a WalR response regulator inhibitor. Walrycin B has potent activity of inhibiting bacteria growth[1][2].
    Walrycin B (Standard)
  • HY-151269
    SARS-CoV-2-IN-26
    Inhibitor
    SARS-CoV-2-IN-23 is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 induces liposomal membrane disruption with an EC50 value of 4.4 μM.
    SARS-CoV-2-IN-26
  • HY-168568
    SARS-CoV-2 Mpro-IN-28
    Inhibitor
    SARS-CoV-2 Mpro-IN-28 (Compound 1K) is an inhibitor of SARS-CoV-2 Mpro with an EC50 value of 24 μM.
    SARS-CoV-2 Mpro-IN-28
  • HY-17367S4
    Atazanavir-d6
    Inhibitor 99.28%
    Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM.
    Atazanavir-d<sub>6</sub>
  • HY-P10803
    FLDKFNHEAEDLFYQSSL
    Inhibitor
    FLDKFNHEAEDLFYQSSL is an 18-residue peptide that binds to SARS-CoV-2 receptor-binding domain (RBD). FLDKFNHEAEDLFYQSSL inhibits the entry of SARS-Cov-2. FLDKFNHEAEDLFYQSSL also interacts with binding residues (Leu455, Phe456, Ala475 and Gln493).
    FLDKFNHEAEDLFYQSSL
  • HY-175498
    RLA-3107
    Inhibitor
    RLA-3107 is an artemisinin regioisomer that blocks ion channels, thereby preventing cations from entering the host cytoplasm. RLA-3107 is also a viroporin inhibitor.
    RLA-3107
  • HY-168599
    SARS-CoV-2 Mpro-IN-31
    Inhibitor
    SARS-CoV-2 Mpro-IN-31 (Compound 18) is an inhibitor of SARS-CoV-2 MPro with an IC50 value of 11 nM. Additionally, SARS-CoV-2 Mpro-IN-31 effectively inhibits the enzymatic activity of the cysteine proteases cathepsin B and cathepsin L, with IC50 values of 24 nM and 1.8 nM, respectively.
    SARS-CoV-2 Mpro-IN-31
Cat. No. Product Name / Synonyms Species Source